Results 221 to 230 of about 890,247 (348)

Systematic review and scoring‐based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children

British Journal of Clinical Pharmacology, EarlyView.
This systematic review identified 112 population pharmacokinetic models of vancomycin in neonates and children. To support rational model selection for model‐informed precision, we developed and applied expert‐driven, transparent criteria that integrate both methodological rigour and clinical relevance.
Zoë Vander Elst, Pieter‐Jan Spiessens, Dorian Vanneste, Nada Dia, Matthias Gijsen, Isabel Spriet, Karel Allegaert, Erwin Dreesen, Anne Smits   +8 more
wiley   +1 more source

Correction: The combination of mupirocin and Kayvirus broadens the decolonization effect against Staphylococcus aureus. [PDF]

Appl Microbiol Biotechnol
Siváková A, Figallová E, Botka T, Vacek L, Tkadlec J, Vrbský J, Osowski M, Petráš P, Kleknerová DP, Dvořáčková M, Urbanová P, Pantůček R, Růžička F.   +12 more
europepmc   +1 more source

Therapeutic drug monitoring of antimicrobials in a paediatric setting: A retrospective single‐centre study

British Journal of Clinical Pharmacology, EarlyView.
Aims Paediatric pharmacokinetics differ significantly from adults due to age‐related physiological changes, necessitating precise dose adjustments. However, data on therapeutic drug monitoring (TDM) implementation in paediatric setting remain limited.
Gianluca Gazzaniga, Stefano Agliardi, Riccardo Giossi, Alice Schianchi, Alessandra Romandini, Thomas Virdis, Silvia Nerini Molteni, Maria Luisa De Angelis, Stefania Paccagnini, Cecilia Gechtman, Alice Proto, Marco Fossati, Silvia Oliveri, Giulia Angela Pattarino, Elena Altieri, Agnese Graziosi, Arianna Pani, Romano Danesi, Stefano Martinelli, Costantino De Giacomo, Francesco Scaglione   +20 more
wiley   +1 more source

Lack of improvement after short‐term topical antistaphylococcal endolysin SA.100 therapy in patients with mild‐to‐moderate atopic dermatitis: Results from a randomized, vehicle‐controlled trial

British Journal of Clinical Pharmacology, EarlyView.
Abstract Atopic dermatitis (AD) is a chronic immune‐mediated inflammatory skin disease. An overgrowth of Staphylococcus aureus (S. aureus) and decreased microbial diversity is apparent in 70%–90% of AD patients. SA.100 is a recombinant endolysin targeting S. aureus that might be a novel treatment for patients with mild‐to‐moderate AD.
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Ismahaan Abdisalaam, Rianne Rijneveld, Erica S. Klaassen, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Benthe Freyee, Karin Platenkamp, Mariette E. van Poelgeest, Robert Rissmann, Martijn B. A. van Doorn, Tessa Niemeyer – van der Kolk   +15 more
wiley   +1 more source

Waves of resistance: Staphylococcus aureus in the antibiotic era

Nature Reviews Microbiology, 2009
H. Chambers, F. DeLeo
semanticscholar   +1 more source

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Naomi Klarenbeek, Marieke L. de Kam, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Vincent de Jong, Benthe Freyee, Martijn B. A. van Doorn, Robert Rissmann, Tessa Niemeyer–van der Kolk   +13 more
wiley   +1 more source

The toxic effects of α-hemolysin and β-hemolysin produced by <i>Staphylococcus aureus</i>. [PDF]

Front Immunol
Zhang Q, Wu Y, Luo D, Fang F.
europepmc   +1 more source

Tobramycin pharmacokinetic and pharmacodynamic targets in people with cystic fibrosis

British Journal of Clinical Pharmacology, EarlyView.
Intravenous tobramycin is a first‐line treatment for Pseudomonas aeruginosa infection in people with cystic fibrosis (CF). Tobramycin exhibits concentration‐dependent activity; however, excess drug exposure can lead to nephrotoxicity and ototoxicity. While dosing typically targets serum peak (Cmax) and trough (Cmin) concentrations, the area under the ...
Kiera H. Harwood, Sarah Bannister, Stephen Duffull, April Martinez, Sarath Ranganathan, Shivanthan Shanthikumar, Amanda Gwee   +6 more
wiley   +1 more source

Elevated urinary glycosaminoglycans in <i>Staphylococcus aureus</i> bacteraemia with endovascular source. [PDF]

J Med Microbiol
Smelter DF, Volk CF, Gandhi R, Sakoulas G, Rose WE.   +4 more
europepmc   +1 more source

One‐Pot Synthesis of a Small Synthetic Ligand for Antibody Purification

Biotechnology and Bioengineering, EarlyView.
One‐pot liquid‐phase synthesis of the synthetic ligand B1Al2A2 enables controllable ligand density and efficient capture of IgG and IgY with high recovery and purity, streamlining small‐ligand affinity purification workflows. ABSTRACT The development of synthetic affinity ligands offers a cost‐effective alternative to traditional biological ligands ...
Carolina Mota Natal, Catarina Domingos, André Nascimento, José Mendes, Afonso B. Ruiz, Ana Margarida Gonçalves Carvalho Dias, Luisa M. Ferreira, Cristina Peixoto, Ana Cecília Afonso Roque   +8 more
wiley   +1 more source